Table 3.

Resistance phenotype, number of isolates, collection period, and antimicrobial activity of enterococci for tedizolid and linezolid.

Microorganism/Study	Antimicrobial	Resistance Phenotype	Nº Isolates	Collection Period	Percent of Isolates (%) Inhibited at MIC (mg/L) of:
					≤0.12	0.25	0.5	1	2	4	8	>8
E. faecalis
Sahm et al. [22]	Tedizolid		634	2011–2012	5.8	54.8	39.1	0.1	0.2
Barber et al. [26]	Tedizolid		100	Before 2016	30.0	69.0	1.0
Pfaller et al. [25]	Tedizolid		559	2014–2015	55.6	44.0	0.4
E. faecium
Sahm et al. [22]	Tedizolid		221	2011–2012	10.4	52.5	35.7	0.9	0.5
Barber et al. [26]	Tedizolid		120	Before 2016	5.0	42.5	26.7	20.8	2.5	2.5
		LR	10					40.0	30.0	30.0
		DNS	25			44.0	12.0	32.0	8.0	4.0
Pfaller et al. [25]	Tedizolid		311	2014–2015	80.4	18.6	0.6	0.0	0.3
		VRE	245		79.2	20.0	0.8
		VSE	66		84.8	13.6	0.0	1.5
					MIC (mg/L)
Klupp et al. [28]					2	4	8	16	32	64	128	256
	Tedizolid	VRE	30	2012–2015	20.0	60.0	10.0	3.3	6.7
	Linezolid	VRE							26.7	20.0	20.0	33.3
Enterococcus spp. (predominantly E. faecalis and E. faecium without differentiating species)					MIC (mg/L)
					≤0.12	0.25	0.5	1	2	4	8	>8
Zurenko et al. [23]	Tedizolid		1241	2008–2013	5.7	50.7	42.2	1.0	0.3	0.1
	Linezolid					0.4	2.7	40.7	54.4	1.4	0.1	0.3
Other enterococci
Sahm et al. [22]	Tedizolid		18	2011–2012	33.3	38.9	27.8
	Tedizolid	VRE	163		10.4	52.2	36.2	0.6	0.6
	Linezolid	VRE					1.2	40.5	57.2	0.5	0	0.6
	Tedizolid	VSE	705		14.2	73.2	12.6
	Linezolid	VSE			0.1	0.5	5.9	51.9	41.3	0.3

Light grey: values under the susceptibility range. DNS: daptomycin-non-susceptible; LR: linezolid resistant; VRE: vancomycin resistant; VSE: vancomycin susceptible.